OSLO/LONDON, 31 August 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today announced the
appointment of John Edminson as Chief Financial Officer, effective 1 October
2022. 

"We are delighted to welcome John to EXACT-Tx as CFO. His strong prior
experience in finance and operations will be pivotal for our further development
of EXACT-Tx", said Dr Per Walday, CEO of EXACT-Tx. "John joins EXACT-Tx at an
exciting time as we continue to expand our international presence and progress
our plans for the future development of ACT®". 

John is a graduate from the Norwegian School of Economics with a Master in
Auditing and Accounting and he built his career foundations working in audit at
KPMG, which included 1.5 years in Boston, USA. He subsequently gained experience
in both finance and operations in a variety of companies, including Telenor,
ACNielsen, and Kistefos, before taking on CFO roles in PatientSky and Questback.


ENDS 

For more information, please contact: 

Dr Per Walday 
Chief Executive Officer
EXACT-Tx 

Email: per.walday@exact-tx.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®).  ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.